Humacyte Valuation
| HUMA Stock | USD 1.12 0.11 8.94% |
Today, the firm appears to be undervalued. Humacyte retains a regular Real Value of $2.72 per share. The prevalent price of the firm is $1.12. Our model calculates the value of Humacyte from evaluating the firm fundamentals such as Return On Equity of -2.5, return on asset of -0.63, and Shares Outstanding of 193 M as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Humacyte's price fluctuation is dangerous at this time. Calculation of the real value of Humacyte is based on 3 months time horizon. Increasing Humacyte's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Humacyte is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Humacyte Stock. However, Humacyte's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.12 | Real 2.72 | Hype 1.12 | Naive 1.27 |
The real value of Humacyte Stock, also known as its intrinsic value, is the underlying worth of Humacyte Company, which is reflected in its stock price. It is based on Humacyte's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Humacyte's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Humacyte helps investors to forecast how Humacyte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Humacyte more accurately as focusing exclusively on Humacyte's fundamentals will not take into account other important factors: About Humacyte Valuation
The stock valuation mechanism determines Humacyte's current worth on a weekly basis. Our valuation model uses a comparative analysis of Humacyte. We calculate exposure to Humacyte's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Humacyte's related companies.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company was founded in 2004 and is headquartered in Durham, North Carolina. Humacyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 145 people.
Humacyte Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 118.5 M | |
| Forward Price Earnings | 23.8095 |
Complementary Tools for Humacyte Stock analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |